Journal
CURRENT ALLERGY AND ASTHMA REPORTS
Volume 17, Issue 3, Pages -Publisher
CURRENT MEDICINE GROUP
DOI: 10.1007/s11882-017-0687-0
Keywords
Immunotherapy and tolerance induction; Regulatory aspects; Allergic rhinitis; Trial design
Categories
Funding
- Merck & Co., Inc., Kenilworth, NJ, USA
Ask authors/readers for more resources
Progress has been made in the harmonization of efficacy and safety outcome measures for allergen immunotherapy (AIT) trials, but unresolved issues still remain. Furthermore, there are discrepancies in recommendations from professional medical societies and regulatory agencies regarding requirements for AIT trials. In this article, we reviewed published recommendations and current data from recent clinical trials, as well as the criteria applied by regulatory authorities for approval of AIT products, to provide updated considerations for conducting phase 3 AIT trials. Topics discussed include analysis of outcomes and trial designs for pediatric and asthma indications, as well as trial designs for perennial allergic rhinoconjunctivitis. In addition, the need for harmonization of safety reporting is emphasized. Considerations presented in this article may further effort to find common ground among professional medical societies and government agencies in developing future recommendations for AIT trial design.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available